183 related articles for article (PubMed ID: 34277801)
21. The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Ono H; Sowa Y; Horinaka M; Iizumi Y; Watanabe M; Morita M; Nishimoto E; Taguchi T; Sakai T
Breast Cancer Res Treat; 2018 Aug; 171(1):43-52. PubMed ID: 29752686
[TBL] [Abstract][Full Text] [Related]
22. The apatinib inhibits breast cancer cell line MDA-MB-231 in vitro by inducing apoptosis, cell cycle arrest, and regulating nuclear factor-κB (NF-κB) and mitogen-activated protein kinase (MAPK) signaling pathways.
Maroufi NF; Vahedian V; Akbarzadeh M; Mohammadian M; Zahedi M; Isazadeh A; Pouremamali F; Taefehshokr S; Heidari M; Rashidi M; Nouri M
Breast Cancer; 2020 Jul; 27(4):613-620. PubMed ID: 32026267
[TBL] [Abstract][Full Text] [Related]
23. A Novel Paclitaxel Derivative for Triple-Negative Breast Cancer Chemotherapy.
Liu Y; Hong G; Mao L; Su Z; Liu T; Liu H
Molecules; 2023 Apr; 28(9):. PubMed ID: 37175072
[TBL] [Abstract][Full Text] [Related]
24. Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancer.
Van Swearingen AED; Sambade MJ; Siegel MB; Sud S; McNeill RS; Bevill SM; Chen X; Bash RE; Mounsey L; Golitz BT; Santos C; Deal A; Parker JS; Rashid N; Miller CR; Johnson GL; Anders CK
Neuro Oncol; 2017 Oct; 19(11):1481-1493. PubMed ID: 28486691
[TBL] [Abstract][Full Text] [Related]
25. Autophagy inhibitor potentiates the antitumor efficacy of apatinib in uterine sarcoma by stimulating PI3K/Akt/mTOR pathway.
Chen S; Yao L
Cancer Chemother Pharmacol; 2021 Aug; 88(2):323-334. PubMed ID: 33978839
[TBL] [Abstract][Full Text] [Related]
26. Synergistic Anti-glioma Effects in Vitro and in Vivo of Enediyne Antibiotic Neocarzinostatin and Paclitaxel via Enhanced Growth Delay and Apoptosis-Induction.
Tianqin G; Chunlei C; Jingjing W
Biol Pharm Bull; 2016 Oct; 39(10):1623-1630. PubMed ID: 27431785
[TBL] [Abstract][Full Text] [Related]
27. Overexpression of miR-361-5p in triple-negative breast cancer (TNBC) inhibits migration and invasion by targeting RQCD1 and inhibiting the EGFR/PI3K/Akt pathway.
Han J; Yu J; Dai Y; Li J; Guo M; Song J; Zhou X
Bosn J Basic Med Sci; 2019 Feb; 19(1):52-59. PubMed ID: 29924958
[TBL] [Abstract][Full Text] [Related]
28. Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil.
Xu Z; Hu C; Chen S; Zhang C; Yu J; Wang X; Lv H; Cheng X
Cancer Manag Res; 2019; 11():4905-4915. PubMed ID: 31213909
[No Abstract] [Full Text] [Related]
29. A paclitaxel and microRNA-124 coloaded stepped cleavable nanosystem against triple negative breast cancer.
Chen C; Shen M; Liao H; Guo Q; Fu H; Yu J; Duan Y
J Nanobiotechnology; 2021 Feb; 19(1):55. PubMed ID: 33632232
[TBL] [Abstract][Full Text] [Related]
30. 4-methylthiobutyl isothiocyanate synergize the antiproliferative and pro-apoptotic effects of paclitaxel in human breast cancer cells.
Kaur H; Singh A; Kaur K; Kumar A; Attri S; Rashid F; Singh S; Bedi N; Tuli HS; Haque S; Alkuwaity K; Tashkandi HM; Harakeh S; Arora S
Biotechnol Genet Eng Rev; 2023 Jan; ():1-25. PubMed ID: 36683273
[TBL] [Abstract][Full Text] [Related]
31. CircRNA_0044556 affects the sensitivity of triple-negative breast cancer cells to paclitaxel by regulating miR-665.
Chen JJ; Shi P; Cui ZC; Jiang N; Ma J
J Chemother; 2024 Jun; ():1-9. PubMed ID: 38850033
[TBL] [Abstract][Full Text] [Related]
32. Addition of docosahexaenoic acid synergistically enhances the efficacy of apatinib for triple-negative breast cancer therapy.
Ma Y; Yu J; Li Q; Su Q; Cao B
Biosci Biotechnol Biochem; 2020 Apr; 84(4):743-756. PubMed ID: 31889475
[TBL] [Abstract][Full Text] [Related]
33. Berberine activates caspase-9/cytochrome c-mediated apoptosis to suppress triple-negative breast cancer cells in vitro and in vivo.
Zhao Y; Jing Z; Lv J; Zhang Z; Lin J; Cao X; Zhao Z; Liu P; Mao W
Biomed Pharmacother; 2017 Nov; 95():18-24. PubMed ID: 28826092
[TBL] [Abstract][Full Text] [Related]
34. Apatinib inhibits paclitaxel resistance of gastric carcinoma cells through VEGFR2 pathway.
Xie Q; Wang J; Wu W; Zhao Y
Am J Transl Res; 2022; 14(1):421-431. PubMed ID: 35173861
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA MEG3 suppresses cell proliferation, migration and invasion, induces apoptosis and paclitaxel-resistance via miR-4513/PBLD axis in breast cancer cells.
Zhu M; Wang F; Mi H; Li L; Wang J; Han M; Gu Y
Cell Cycle; 2020 Dec; 19(23):3277-3288. PubMed ID: 33121324
[TBL] [Abstract][Full Text] [Related]
36. The effect of apatinib combined with chemotherapy or targeted therapy on non-small cell lung cancer in vitro and vivo.
Liu M; Wang X; Li H; Xu L; Jing L; Jiang P; Liu B; Li Y
Thorac Cancer; 2019 Oct; 10(10):1868-1878. PubMed ID: 31486270
[TBL] [Abstract][Full Text] [Related]
37. MicroRNA-5195-3p enhances the chemosensitivity of triple-negative breast cancer to paclitaxel by downregulating EIF4A2.
Liu M; Gong C; Xu R; Chen Y; Wang X
Cell Mol Biol Lett; 2019; 24():47. PubMed ID: 31308851
[TBL] [Abstract][Full Text] [Related]
38. Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway.
Meng X; Wang H; Zhao J; Hu L; Zhi J; Wei S; Ruan X; Hou X; Li D; Zhang J; Yang W; Qian B; Wu Y; Zhang Y; Meng Z; Guan L; Zhang H; Zheng X; Gao M
Front Oncol; 2020; 10():217. PubMed ID: 32219060
[No Abstract] [Full Text] [Related]
39. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines.
Ye J; Xia X; Dong W; Hao H; Meng L; Yang Y; Wang R; Lyu Y; Liu Y
Int J Nanomedicine; 2016; 11():4125-40. PubMed ID: 27601899
[TBL] [Abstract][Full Text] [Related]
40. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway.
Hu H; Zhu J; Zhong Y; Geng R; Ji Y; Guan Q; Hong C; Wei Y; Min N; Qi A; Zhang Y; Li X
Ann Transl Med; 2021 Mar; 9(5):410. PubMed ID: 33842631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
